Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Eyes and Vision · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 100%

Anti‐VEGF vs control

Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration

Summary of findings: anti‐VEGF treatment leads to higher loss of fewer than 15 letters visual acuity at 1 year compared with control (high certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 1.4 [1.27, 1.55]
6 studies · 2667 participants
High

Summary of findings: bevacizumab vs ranibizumab

Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration

Summary of findings: bevacizumab showed no clear difference in loss of fewer than 15 letters visual acuity at 1 year compared with ranibizumab (high certainty).

1 finding from 1 review

Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
RR 1 [0.98, 1.02]
8 studies · 3144 participants
High